SCHEMBL15217802

SCHEMBL15217802

CC(C)N1CCN(N2CCN(C)CC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.40
KCNH2 Q12809 4/20 0.37
CHRM2 P08172 3/20 0.37
CHRM1 P11229 3/20 0.37
CYP2D6 P10635 3/20 0.37
ADRA2A P08913 2/20 0.37
DRD1 P21728 2/20 0.37
DRD3 P35462 2/20 0.37
SLC6A3 Q01959 2/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM3 P20309 1/20 0.37
ADRA1D P25100 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HRH1 P35367 1/20 0.37
OPRM1 P35372 1/20 0.37
HTR2B P41595 1/20 0.37
CHRNA7 P36544 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22753497 0.91 MC4R (0.44) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL16316010 0.91 MC4R (0.44) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL81580 0.91 MC4R (0.44) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL23791294 0.83 MC4R (0.40) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL16316013 0.81 KCNH2 (0.41) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL81651 0.81 KCNH2 (0.41) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL10287114 0.81 MC4R (0.39) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL26789060 0.81 KCNH2 (0.41) MC4RKCNH2CHRM2CHRM1CYP2D6
SCHEMBL10151423 0.80 CHRNA7 (0.36) KCNH2CYP2D6CHRNA7KDM4EALDH1A1
SCHEMBL8255596 0.80 CHRNA7 (0.36) KCNH2CYP2D6CHRNA7KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180022730-A1 SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-01-25 US disclosed
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 MC4R 3407/4885KCNH2 1258/4885CHRM2 4773/4885
US-20180022730-A1 SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF DDR1, DDR2, DDRGK1 MC4R 2819/4885KCNH2 4553/4885CHRM2 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.